AC Immune (NASDAQ:ACIU) Stock Rating Reaffirmed by HC Wainwright

AC Immune (NASDAQ:ACIU)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued on Friday, Benzinga reports. They presently have a $16.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 357.14% from the company’s previous close.

AC Immune Stock Performance

ACIU stock remained flat at $3.50 during mid-day trading on Friday. 182,176 shares of the company’s stock traded hands, compared to its average volume of 129,036. The stock has a market cap of $295.58 million, a price-to-earnings ratio of -4.93 and a beta of 1.03. AC Immune has a twelve month low of $1.78 and a twelve month high of $5.14. The firm’s 50 day moving average is $3.61 and its two-hundred day moving average is $3.39.

Institutional Trading of AC Immune

Several hedge funds and other institutional investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. bought a new stake in AC Immune during the 4th quarter worth approximately $48,000. Tower Research Capital LLC TRC grew its stake in AC Immune by 4,935.4% in the 3rd quarter. Tower Research Capital LLC TRC now owns 19,638 shares of the company’s stock worth $56,000 after buying an additional 19,248 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of AC Immune in the 4th quarter valued at $58,000. Nixon Peabody Trust Co. purchased a new stake in shares of AC Immune in the 4th quarter valued at $64,000. Finally, Balyasny Asset Management LLC purchased a new stake in shares of AC Immune in the 3rd quarter valued at $82,000. Institutional investors own 19.17% of the company’s stock.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.